Capital Impact Advisors’s XBiotech XBIT Stock Holding History

Capital Impact Advisors’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-52,289	Closed	-$862K	–	154
2017 Q1	$862K	Buy	+52,289	New	+$685K	0.34%	145

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Impact Advisors's XBIT Position: Q2 2017 in Review

Capital Impact Advisors sold out of XBiotech (XBIT) in Q2 2017, closing a stake of 52,289 shares — an estimated $862K sold.

Capital Impact Advisors first reported a position in XBIT in Q1 2017 and held it in 1 quarter. The position peaked at $862K in Q1 2017. 46 funds tracked by Wall St. Rank hold XBIT as of Q2 2017.

Capital Impact Advisors reported no remaining XBiotech position as of Q2 2017 after selling out during the quarter.
Capital Impact Advisors sold 52,289 XBiotech shares in Q2 2017, an estimated $862K.
Capital Impact Advisors first reported a position in XBiotech in Q1 2017 and held it in 1 quarter.
Capital Impact Advisors's XBiotech position peaked at $862K in Q1 2017.
46 funds tracked by Wall St. Rank held XBiotech as of Q2 2017.

Based on Capital Impact Advisors's 13F filing for Q2 2017, filed 18 Jul 2017.